Analyst Price Targets — CODX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 14, 2022 6:26 am | — | H.C. Wainwright | $180.00 | $109.50 | Benzinga | HC Wainwright & Co. Maintains Buy on Co-Diagnostics, Lowers Price Target to $6 |
| August 15, 2022 6:19 am | — | H.C. Wainwright | $270.00 | $134.40 | Benzinga | HC Wainwright & Co. Maintains Buy on Co-Diagnostics, Lowers Price Target to $9 |
| May 16, 2022 6:59 am | — | H.C. Wainwright | $360.00 | $136.50 | Benzinga | HC Wainwright & Co. Maintains Buy on Co-Diagnostics, Lowers Price Target to $12 |
Latest News for CODX
Shipments of laboratory equipment and other mosquito abatement materials to overseas USAF base represent first international expansion of Vector Smart product line SALT LAKE CITY, Sept. 1, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the first…
Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT SALT LAKE CITY, Aug. 18, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Company Chief…
Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript
Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-Enabled Capabilities SALT LAKE CITY, Aug. 13, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the…
Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro ® instrument in decentralized point-of-care settings SALT LAKE CITY, Aug. 6, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has submitted a…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CODX.
U.S. House Trading
No House trades found for CODX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.